清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Anti-CD47 and Anti-PDL1 Immunotherapy Synergize for Anti-tumor Activity in Preclinical Models of Head and Neck Cancer

医学 头颈部癌 CD47型 免疫疗法 头颈部 癌症 肿瘤科 癌症研究 免疫学 内科学 抗体 外科
作者
Nayanah Siva,Jin Dai,Jonathan Chardon-Robles,John A. Ligon,Frances Weidert,Elias Sayour,Emrullah Yilmaz,Daniel J. McGrail,Andrew G. Sikora,Roberto Rangel,Natalie L. Silver
出处
期刊:International Journal of Radiation Oncology Biology Physics [Elsevier]
卷期号:118 (5): e85-e85
标识
DOI:10.1016/j.ijrobp.2024.01.189
摘要

Purpose/Objective(s) Recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, with only ∼20% of patients responding to anti-PD-1 checkpoint immunotherapy. CD47 is another targetable immune checkpoint. By interacting with SIRPα, CD47 triggers a "don't eat me" signal to inhibit macrophage phagocytosis which is upregulated in the HNSCC tumor microenvironment. The aim of our study was to examine the effect of anti-CD47 as monotherapy and in combination with anti-PD-L1/PD-1 checkpoint blockade, on tumor growth response and survival in syngeneic orthotopic models of HNSCC. Materials/Methods Syngeneic murine HNSCC cell lines were injected orthotopically (tongue) into C57/B6 mice: MOC1, ROC1, and ROC3 (n=5-10 per group). The MOC1 mice were then subjected to immunotherapy intraperitoneally with either control (IgG), anti-CD47, anti-PD-L1 or the combination. ROC1 and ROC3 mice were injected intratumorally with anti-CD-47 and anti-PD-1 was administered intraperitoneally to ROC3 mice in combination with anti-PD-1. Tumor rechallenge (via inoculation of cancer cells was performed in mice exhibiting complete responses to therapy). Tumor volumes were recorded, and survival curves were generated. RNA was isolated from treated tumors and mRNA expression data was collected. Statistical analysis was performed. Results In MOC1 implanted mice, anti-CD47 monotherapy resulted in no significant difference in tumor volume or survival compared to control (IgG). However, when used in combination with anti-PD-L1, anti-CD47 treatment resulted in a statistically significant decrease in tumor volume and significantly increased overall survival (p<0.05). There were 6/10 complete responders in the combination group (and no mice grew tumors after re-challenge at 100 days). ROC3 implanted mice treated with anti-CD47 treatment showed a significant decrease in tumor volume with monotherapy, compared to control, and maintained complete responses after tumor cell re-challenge (p<0.05). Conversely, the more aggressive ROC1 mouse model showed no significant difference in treatment arms which included anti-CD47, anti-PD-1 and the combination. RNA expression analysis of MOC1 tumors treated with anti-PD-L1 demonstrated significantly increased CD47 expression. Conclusion We have demonstrated that anti-CD47 and anti-PD-L1 have a synergistic effect in MOC1 tumor models while monotherapy with anti-CD47 works effectively in the ROC3 model. Combination therapy showed no response in the ROC1 model. PD-L1 treatment of MOC1 tumors caused increased expression of CD47 in tumors, indicating that increased CD47 may be an immunosuppressive mechanism that may contribute to PD-L1 immune checkpoint inhibitor resistance. Combining anti-CD47 with anti-PD-L1 immunotherapy may be effective in HNSCC patients with higher baseline immune cell infiltration. Recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) has a poor prognosis, with only ∼20% of patients responding to anti-PD-1 checkpoint immunotherapy. CD47 is another targetable immune checkpoint. By interacting with SIRPα, CD47 triggers a "don't eat me" signal to inhibit macrophage phagocytosis which is upregulated in the HNSCC tumor microenvironment. The aim of our study was to examine the effect of anti-CD47 as monotherapy and in combination with anti-PD-L1/PD-1 checkpoint blockade, on tumor growth response and survival in syngeneic orthotopic models of HNSCC. Syngeneic murine HNSCC cell lines were injected orthotopically (tongue) into C57/B6 mice: MOC1, ROC1, and ROC3 (n=5-10 per group). The MOC1 mice were then subjected to immunotherapy intraperitoneally with either control (IgG), anti-CD47, anti-PD-L1 or the combination. ROC1 and ROC3 mice were injected intratumorally with anti-CD-47 and anti-PD-1 was administered intraperitoneally to ROC3 mice in combination with anti-PD-1. Tumor rechallenge (via inoculation of cancer cells was performed in mice exhibiting complete responses to therapy). Tumor volumes were recorded, and survival curves were generated. RNA was isolated from treated tumors and mRNA expression data was collected. Statistical analysis was performed. In MOC1 implanted mice, anti-CD47 monotherapy resulted in no significant difference in tumor volume or survival compared to control (IgG). However, when used in combination with anti-PD-L1, anti-CD47 treatment resulted in a statistically significant decrease in tumor volume and significantly increased overall survival (p<0.05). There were 6/10 complete responders in the combination group (and no mice grew tumors after re-challenge at 100 days). ROC3 implanted mice treated with anti-CD47 treatment showed a significant decrease in tumor volume with monotherapy, compared to control, and maintained complete responses after tumor cell re-challenge (p<0.05). Conversely, the more aggressive ROC1 mouse model showed no significant difference in treatment arms which included anti-CD47, anti-PD-1 and the combination. RNA expression analysis of MOC1 tumors treated with anti-PD-L1 demonstrated significantly increased CD47 expression. We have demonstrated that anti-CD47 and anti-PD-L1 have a synergistic effect in MOC1 tumor models while monotherapy with anti-CD47 works effectively in the ROC3 model. Combination therapy showed no response in the ROC1 model. PD-L1 treatment of MOC1 tumors caused increased expression of CD47 in tumors, indicating that increased CD47 may be an immunosuppressive mechanism that may contribute to PD-L1 immune checkpoint inhibitor resistance. Combining anti-CD47 with anti-PD-L1 immunotherapy may be effective in HNSCC patients with higher baseline immune cell infiltration.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
37秒前
FFFFFF发布了新的文献求助10
40秒前
斯文败类应助FFFFFF采纳,获得10
46秒前
FFFFFF完成签到,获得积分10
55秒前
leo完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
zz发布了新的文献求助10
1分钟前
赘婿应助zz采纳,获得10
1分钟前
吴彦祖发布了新的文献求助10
1分钟前
先锋完成签到 ,获得积分10
1分钟前
2分钟前
自由的无色完成签到 ,获得积分10
2分钟前
4分钟前
zz发布了新的文献求助10
4分钟前
深情安青应助科研通管家采纳,获得10
4分钟前
方白秋完成签到,获得积分10
5分钟前
吴彦祖发布了新的文献求助10
5分钟前
热心芸完成签到,获得积分10
6分钟前
6分钟前
小二郎应助科研通管家采纳,获得10
6分钟前
吴彦祖发布了新的文献求助10
6分钟前
6分钟前
李露露发布了新的文献求助10
6分钟前
忧心的从蓉完成签到,获得积分10
9分钟前
9分钟前
Jiang发布了新的文献求助10
10分钟前
枯藤老柳树完成签到,获得积分10
10分钟前
10分钟前
Jiang完成签到,获得积分10
10分钟前
zz发布了新的文献求助10
11分钟前
LIUYONG应助zz采纳,获得10
11分钟前
李露露完成签到 ,获得积分10
11分钟前
白菜完成签到 ,获得积分10
12分钟前
科研通AI2S应助吴彦祖采纳,获得10
12分钟前
12分钟前
吴彦祖发布了新的文献求助10
12分钟前
方琼燕完成签到 ,获得积分10
13分钟前
安安滴滴完成签到 ,获得积分10
14分钟前
yy完成签到,获得积分10
14分钟前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
A Chronicle of Small Beer: The Memoirs of Nan Green 1000
From Rural China to the Ivy League: Reminiscences of Transformations in Modern Chinese History 900
Migration and Wellbeing: Towards a More Inclusive World 900
Eric Dunning and the Sociology of Sport 850
QMS18Ed2 | process management. 2nd ed 800
Operative Techniques in Pediatric Orthopaedic Surgery 510
热门求助领域 (近24小时)
化学 医学 材料科学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 免疫学 细胞生物学 电极
热门帖子
关注 科研通微信公众号,转发送积分 2913368
求助须知:如何正确求助?哪些是违规求助? 2550091
关于积分的说明 6900298
捐赠科研通 2213417
什么是DOI,文献DOI怎么找? 1176416
版权声明 588231
科研通“疑难数据库(出版商)”最低求助积分说明 576113